First-line treatment of follicular lymphoma–a patient-oriented algorithm

References

• Groves F D, Linet M A, Travis L B, Devesa S S. Cancer surveillance series: non Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240–1251
   PubMed Web of Science ®Google Scholar
• Van Besien K, Sobocinski K A, Rowlings P A, Murphy S C, Armitage J O, Bishop M R, et al. Allogenic bone marrow transplantation for low grade lymphoma. Blood 1998; 92: 1832–1836
   PubMed Web of Science ®Google Scholar
• Tan D, Rosenberg S A, Levy R, Lavori P, Tibshirani R, Hoppe R T, et al. Survival in follicular lymphoma: the Stanford experience, 1960–2003. Blood (Suppl) (ASH Annual Meeting Abstracts) 2007; 110: 1005A, (Abstract #3428)
   Google Scholar
• Fisher R I, LeBlanc M, Press O W, Maloney D G, Unger J M, Miller T P. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447–8452
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F, Hagemeister F B, Ayers G D, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582–1589
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Motta M, Wannesson L, Gracia E, Belisario F V, et al. Are we changing the survival of follicular lymphomas? Patterns of outcome in the patients treated at the oncology Institute of Southern Switzerland from 1979 to 2006. Eur J Cancer Suppl 2007; 5: 346, (Abstract O #6005)
   Web of Science ®Google Scholar
• Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007; 109: 2077–2082
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, White J, Armitage J O, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Swerdlow S H, Campo E, Lee H N, Jaffe E S, Pileri S A, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Follicular Lymphoma, Lyon 2008; 222–223
   Google Scholar
• Bartlett N L, Rizeq M, Dorfmann R F, Halpern J, Horning S J. Follicular large-cell lymphoma: intermediate or low grade?. J Clin Oncol 1994; 12: 1349–1357
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 10: 1419–1432
   Google Scholar
• Martin A R, Weisenburger D D, Chan W C, Ruby E I, Anderson J R, Vose J M, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 8: 3671–3678
   Google Scholar
• Glas A M, Kersten M J, Delahaye L S, Witteveen A T, Kibbelaar R E, Velds A, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301–307
   PubMed Web of Science ®Google Scholar
• Dave S S, Wright G, Tan B, Rosenwald A, Gascoyne R D, Chan W C, et al. Predicition of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. A clinicopathologic study that identifies gene-expression signatures derived from FL biopsy specimens that predict for length of survival at time of initial diagnosis. N Engl J Med 2004; 351: 2159–2169
   PubMed Web of Science ®Google Scholar
• Guadagnolo B A, Li S, Neuberg D, Ng A, Hua L, Silver B, et al. Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 64: 928–934
   PubMed Web of Science ®Google Scholar
• Macmanus M P, Hoppe R T. Is radiotherapy curative for stage one and two low-grade follicular lymphoma?. J Clin Oncol 1996; 14: 1282–1290
   PubMed Web of Science ®Google Scholar
• Wilder R B, Jones D, Tucker S L, Fuller L M, Ha C S, McLaughlin P, et al. Long-term results in stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219–1227
   PubMed Web of Science ®Google Scholar
• De Neve W J, Lybeert M L, Meerwaldt J H. Low-dose total body irradiation in non-Hodgkin lymphoma: short and long term toxicity and prognostic factor. Am J Clin Oncol 1990; 13: 280–284
   PubMed Web of Science ®Google Scholar
• Lybeert M L, Meerwaldt J H, De Neve W J. Long term results of low-dose total body irradiation for advanced non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 1987; 13: 1167–1172
   PubMed Web of Science ®Google Scholar
• Murtha A, Rupnow B, Hansosn J, Knox S J, Hoppe R. Long-term follow-up of patients with III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phy 2001; 49: 3–15
   PubMed Web of Science ®Google Scholar
• Van Besien K, Loberiza F R, Bajorunaite R, Armitage J O, Bashey A, Burns L J, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529
   PubMed Web of Science ®Google Scholar
• Bierman P J, Sweetenham J W, Loberiza F R, Taghipour G, Lazarus H M, Rizzo J D, et al. Syngeneic hematopoietic stem cell transplantation for non hodgkin lymphoma: a comparison with allogeneic and autologous transplantation. The Lymphoma Working Committee of the International Bone Marrow Transplant Reistry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003; 21: 3744–3753
   PubMed Web of Science ®Google Scholar
• Verdonck L F, Dekker A W, Lokhorst H M, Petersen E J, Nieuwenhuis H K. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non hodgkin's lymphoma. Blood 1997; 90: 4201–4205
   PubMed Web of Science ®Google Scholar
• Van Besien K W, Khouri I F, Giralt S A, McCarthy P, Mehra R, Andersson B S, et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13: 1096–1102
   PubMed Web of Science ®Google Scholar
• Rohatiner A Z, Gregory W M, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005; 23: 2215–2223
   PubMed Web of Science ®Google Scholar
• Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 2004; 104: 584, (ASH Annual Meeting Abstracts)
   Web of Science ®Google Scholar
• Salles G, Foussard C, Nicolas M, Franck M, Chantal D, Thierry L, et al. Rituximab added to CHVP+IFN improves the outcome of follicular lymphoma patients: first analysis of the GELA-GOELAMS FL-2000 randomised trial. Blood 2004; 4: 49
   Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy polus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Hiddenmann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with Rituximab added to the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospectve randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Grillo-López A J, White C A, Saleh M, Gordon L, LoBuglio A F, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276
   PubMed Web of Science ®Google Scholar
• Schulz H, Skoetz N, Bohlius J, Trelle S, MD, Kober T, Greb A, et al. Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the teatment of patients with indolent non-hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis. Blood (Suppl)(ASH Annual Meeting Abstracts) 2005; 106, (Abstract 351)
   Google Scholar
• Zinzani P L, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654–2661
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, Catalano J V, Dmoszynska A, Raposo J C, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579–4586
   PubMed Web of Science ®Google Scholar
• Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin lymphomas. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• (a) Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimstine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110–1117
   PubMed Web of Science ®Google Scholar
• Advani R, Rosenberg S A, Horning S J. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454–1459
   PubMed Web of Science ®Google Scholar
• Ardenshna K M, Smith P, Norton A, Hancock B W, Hoskin P J, MacLennan K A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516–522
   PubMed Web of Science ®Google Scholar
• Montoto S, Davies A J, Matthews J, Calaminici M, Norton A J, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 2426–2433
   PubMed Web of Science ®Google Scholar
• Al-Tourah A J, Gill K K, Chhanabhai M, Hoskins P J, Klasa R J, Savage K J, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin lymphoma. J Clin Oncol 2008; 26: 5165–5169
   PubMed Web of Science ®Google Scholar
• van Oers M H, Klasa R, Marcus R E, Wolf M, Kimby E, Gascoyne R D, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301
   PubMed Web of Science ®Google Scholar
• Galton D A, Israels L G, Nabarro J D, Till M. Clinical trial of p (dichloroethylamino) phenylbutyric acid (CB 1384) in malignant lymphoma. BMJ 1955; 2: 1172–1176
   PubMed Web of Science ®Google Scholar
• Johnson P WM, Rohatiner A ZS, Whelan J S, Price C GA, Love S, Jim J, et al. Patterns of Survival I patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147
   PubMed Web of Science ®Google Scholar
• Peterson B A, Petroni G R, Frizzera G, Barcos M, Bloomfield C D, Nissen N I, et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 2003; 21: 5–15
   PubMed Web of Science ®Google Scholar
• Leone G, Voso M T, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001; 41: 255–276
   PubMed Web of Science ®Google Scholar
• Larson R A, Le Beau M M. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact 2005; 153–154: 187–195
   PubMed Web of Science ®Google Scholar
• Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002; 128: 603–609
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin P J, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590–1596
   PubMed Web of Science ®Google Scholar
• Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995; 86: 1710–1716
   PubMed Web of Science ®Google Scholar
• Betticher D C, Zucca E, von Rohr A, Egger T, Radford J A, Ambrosetti A, et al. 2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol 1996; 7: 793–799
   PubMed Web of Science ®Google Scholar
• Colombat P, Brousse N, Morschhauser F, Franchi-Rezgui P, Soubeyran P, Delwail V, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma: Survival analyses with extended follow-up of 7 years. Blood (ASH Annual Meeting Abstracts) 2006; 108, Abstract 486
   Google Scholar
• Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16: 1675–1682
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S B, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule (SAKK 35/98). Blood 2004; 103: 4416–4423
   PubMed Web of Science ®Google Scholar
• Martinelli G, Laszlo D, Bertolini F, Pastano R, Mancuso P, Calleri A, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's Lymphoma. Br J Haematol 2003; 123: 21–27
   Web of Science ®Google Scholar
• Rummel M J, Al-Batran S E, Kim S Z, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383–3389
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005; 23: 694–704
   PubMed Web of Science ®Google Scholar
• Rummel M J, von Grunhagen U, Niederle N, Rothmann F, Ballo H, Weidmann E, et al. On behalf of the StiL. Bendamustin plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas–first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (Suppl) (ASH Annual Meeting Abstracts) 2007; 110, (Abstract 385 Oral Session)
   Google Scholar
• Robak T, Smolewski P, Cebula B, Szmigielska-Kaplon A, Chojnowski K, Blonski J Z. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107: 1542–1550
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Tuck M, Estes J, Kolstad A, Ross C W, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Gordon L I, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase I/II study. Blood 2004; 103: 4429–4431
   PubMed Web of Science ®Google Scholar
• Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, et al. Combined Cyclophosphamide, Vincistine, Doxirubicin and Prednisone (CHOP) improves response rates but not survivial and has lower hematologic toxicity compared with combined Mitoxantrone, Chlorambucil and Prednisone (MCP) in follicular and mantle cell lymphomas. Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107: 1014–1022
   PubMed Web of Science ®Google Scholar
• Flinn I W, Byrd J C, Morrison C, Jamison J, Diehl L F, Murphy T, et al. Fludarabine and cyclophosphamied with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71–75
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Montserrat E, Bosch F, Escoda L, Terol M J, Marin P, et al. Low-grade lymphoma: clinical and prognostic studies in a series of 143 patients from a single institution. Leuk Lymphoma 1994; 15: 159–165
   PubMed Web of Science ®Google Scholar
• Peterson B A, Petroni G R, Frizzera G, Barcos M, Bloomfield C D, Nissen N I, et al. Prolonged single agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukaemia group B. J Clin Oncol 2003; 21: 5–15
   PubMed Web of Science ®Google Scholar
• Longo D L, Soung R C, Hubbard S M, Wesley M, Fisher R I, Jaffe E, et al. Prolonged initial remission in patient with nodular mixed lymphoma. Ann Intern Med 1984; 100: 651–656
   PubMed Web of Science ®Google Scholar
• Rigacci L, Federico M, Martelli M, Zinzani P L, Cavanna L, Bellesi G, et al. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk Lymphoma 2003; 44: 1911–1917
   PubMed Web of Science ®Google Scholar
• Glick J H, Barnes J M, Ezdinli E Z, Berard C W, Orlow E L, Bennett J M. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 1981; 58: 920–925
   PubMed Web of Science ®Google Scholar
• Tse W W, Lazarus H M, Van Besien K. Stem cell transplantation in follicular lymphoma: progress at last? Comprehensive review of the role of autologous and allogenic stem cell transplantation in FL including issues regarding purging and reduced intensity conditioning. Bone Marrow Transplant 2004; 34: 929–938
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in Lymphoma Study Group. Blood 2004; 104: 2667–2674
   PubMed Web of Science ®Google Scholar
• Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GEOLAMS. Blood 2005; 105: 3817–3823
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926–4933
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004–4013
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Shaffer D W, Lackey V L, Manuel Grimaldi M, Anthony Greco A F. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23: 1088–1095
   PubMed Web of Science ®Google Scholar
• Howard S H, Edie W, Randy D G, Teresa S R, Thomas M H, Leo I G, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood (Suppl) (ASH Annual Meeting Abstracts) 2005; 106: 349
   Google Scholar
• Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008; 49: 102–112
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Bischof-Delaloye B, Radford J A, Rohatiner A, Salles G, Van Hoof A, et al. 90Y-Ibritumomab Tiuxetan (Zevalin) consolidation of first remission in advanced stage follicular non-hodgkin's lymphoma: first results of the international randomized phase 3 first-line indolent trial (FIT) in 414 patients. Blood (ASH Annual Meeting Abstracts) 2007; 110, (Abstract 643)
   Google Scholar